References
Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.
Cashen AF, Schiller GJ, O’Donnell MR, Multicenter DiPersio JF . phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556–561.
Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008; 112: 1366–1373.
Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 2007; 67: 1370–1377.
Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605–613.
Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 2007; 67: 1997–2005.
Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 2011; 6: e19027.
San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746–1751.
Stone RM . Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Best Pract Res Clin Haematol 2011; 24: 509–514.
Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332–341.
Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007; 2: e399.
Bullinger L, Ehrich M, Dohner K, Schlenk RF, Dohner H, Nelson MR et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010; 115: 636–642.
Acknowledgements
This work was supported in part by the Leukemia SPORE, CA100632 and by a grant from Eisai Pharmaceuticals.
Author Contributions
FR designed the research; RC performed the experiments and JJ performed flow cytometry; and YB, HK, JJ, JA, SF, GGM, GB, EJ, ZE, JC, JPI and FR performed the research, analyzed the data and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Consultant or advisory role: Jean-Pierre Issa, GSK, Syndax; Farhad Ravandi, Eisai and Johnson and Johnson; honoraria: Jean-Pierre Issa, Celgene, Novartis, Johnson and Johnson; Farhad Ravandi, Eisai and Johnson and Johsnon; research funding: Jean-Pierre Issa, MERC, Eisai, Celgene; Stephan Faderl, Eisai; Gautam Borthakur, Eisai; Jorge Cortes, Eisai; Hagop Kantarjian, Celgene; Farhad Ravandi, Eisai and Johnson and Johsnon.
Rights and permissions
About this article
Cite this article
Boumber, Y., Kantarjian, H., Jorgensen, J. et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26, 2428–2431 (2012). https://doi.org/10.1038/leu.2012.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.153
- Springer Nature Limited
This article is cited by
-
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
International Journal of Hematology (2023)
-
Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
Experimental Hematology & Oncology (2020)
-
Clinical update on hypomethylating agents
International Journal of Hematology (2019)
-
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
Leukemia (2017)
-
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Leukemia (2017)